Promega builds plant to produce regulated products

Published: 29-Aug-2011
Manufacturing Analysis

Including sample preparation systems and reagents

Promega Corporation, based in Madison, Wisconsin, US, has held a ground-breaking ceremony for a new cGMP facility to support business growth and customers who need FDA-regulated molecular biology products. These include sample preparation systems and reagents, which are part of diagnostic and medical tests sold by human diagnostic test providers.

The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.

‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.

Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.

Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

See more

You may also like

Ingredients

Promega unveils cellular target engagement technology

Read more
TarSeer BRETSA platform enables early-stage studies for difficult proteins in drug discovery

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  4. See. Try. Believe. Experience the Lyza 7000 FTIR with a 70-day risk free trial Laboratories can now evaluate the Lyza 7000 FTIR spectrometer in their own environment through a new 70-day, no-cost, no-risk trial program. The initiative allows teams to run real samples, follow existing SOPs, and fully explore the instrument’s capabilities before making a purchase decision
  5. Andelyn Biosciences and ENCell partner to create US-APAC gene therapy manufacturing corridor The company has signed a collaboration agreement with South Korea's ENCell to establish a dual-hemisphere manufacturing platform linking US and Asia-Pacific facilities, enabling in-country production for regional clinical trials

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Ingredients

Promega unveils cellular target engagement technology

TarSeer BRETSA platform enables early-stage studies for difficult proteins in drug discovery
Manufacturing

Promega opens new Shanghai facility

Provides additional r&d and cGMP manufacturing capabilities
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Analysis

Introducing Shimadzu’s MultiNA II: Redefining precision in life science analysis

Designed with users in mind, the MultiNA II MCE-301 is a fully automated microchip electrophoresis system designed to accelerate and simplify genetic analysis workflows in pharmaceutical and biopharmaceutical laboratories
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Subscribe now